By Fineline Cube Ocumension Therapeutics (HKG: 1477) announced that all subjects have been enrolled as scheduled in the Chinese Phase III clinical trial of OT‑211 (TRYPTYR, acotremon ophthalmic solution), a novel therapy for dry eye disease. The milestone keeps the China registrational program of OT‑211 — the world’s first TRPM8 receptor agonist approved for dry eye disease, introduced into China under a strategic partnership between Ocumension and Alcon — on track with the asset’s global pivotal studies.
Trial Design – China Phase III Study of OT‑211
| Item | Detail |
|---|---|
| Phase / Design | Phase III, randomized, double‑blind, vehicle‑controlled, parallel‑group, multicenter study |
| Enrollment | 398 subjects with moderate‑to‑severe dry eye disease (fully enrolled as scheduled) |
| Primary Endpoint | Proportion of subjects with an increase of ≥10 mm from baseline in unanesthetized Schirmer’s test score at Day 14 |
| Endpoint Alignment | Consistent with the primary endpoints of OT‑211’s global pivotal Phase III trials (COMET‑2 and COMET‑3) |
| Status | Enrollment complete; efficacy and safety evaluation ongoing |
Drug Profile & Mechanism of Action
- Molecule: OT‑211 (TRYPTYR, acotremon ophthalmic solution), a novel ophthalmic therapy for dry eye disease
- Target / Class: TRPM8 receptor agonist — the world’s first TRPM8 agonist approved for the treatment of dry eye disease
- Partnership: Introduced into China under a strategic partnership between Ocumension Therapeutics and Alcon
- Global Evidence Base: Primary endpoint harmonized with the global COMET‑2 and COMET‑3 pivotal trials, supporting cross‑regional data comparability
Market Impact & Outlook
- Execution on schedule: Full enrollment of the 398‑subject study as planned de‑risks the China registrational timeline for OT‑211 and supports a predictable path toward NMPA submission
- First‑in‑class positioning: As the world’s first approved TRPM8 receptor agonist for dry eye disease, OT‑211 brings a differentiated mechanism to one of ophthalmology’s largest and most competitive markets
- Bridgeable endpoints: The aligned Schirmer’s test primary endpoint with COMET‑2 and COMET‑3 strengthens the prospect of consistent evidence across the China and global programs
- Strategic partnership leverage: The Ocumension–Alcon collaboration combines local development strength with global commercial and clinical resources in a condition affecting a large patient population in China
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the clinical development timeline, trial outcomes, regulatory approval, and commercial potential of OT‑211 in dry eye disease. Actual results may differ materially due to clinical, regulatory, competitive, and market risks. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech